Conference Proceedings

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in >= second-line recurrent or metastatic cervical cancer

KS Tewari, I Vergote, A Oaknin, E Alvarez, S Gaillard, S Lheureux, D Rischin, AD Santin, M Feng, M Mathias, M Fury, I Lowy, BJ Monk

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2018

Grants

Funding Acknowledgements

The study was sponsored by Regeneron Pharmaceutical, Inc. and Sanofi.